167 related articles for article (PubMed ID: 37614433)
1. FIB‑4 index and serum α‑fetoprotein are useful predictors of hepatocellular carcinoma occurrence in hepatitis B patients with nucleos(t)ide analogs therapy.
Kuwano A; Miyazaki M; Yada M; Tanaka K; Koga Y; Masumoto A; Motomura K
Exp Ther Med; 2023 Sep; 26(3):441. PubMed ID: 37614433
[TBL] [Abstract][Full Text] [Related]
2. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
5. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y
J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305
[TBL] [Abstract][Full Text] [Related]
6. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
[TBL] [Abstract][Full Text] [Related]
7. Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC.
Hui VW; Chan SL; Wong VW; Liang LY; Yip TC; Lai JC; Yuen BW; Luk HW; Tse YK; Lee HW; Chan HL; Wong GL
JHEP Rep; 2020 Dec; 2(6):100152. PubMed ID: 33024950
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J; Akahane T; Kobayashi T; Kimura O; Sato K; Ninomiya M; Iwata T; Takai S; Kisara N; Sato T; Nagasaki F; Miura M; Nakamura T; Umetsu T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A;
Hepatol Res; 2024 Feb; 54(2):131-141. PubMed ID: 37621201
[TBL] [Abstract][Full Text] [Related]
9. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma.
Tseng TC; Liu CJ; Su TH; Yang WT; Chen CL; Yang HC; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
Am J Gastroenterol; 2017 Oct; 112(10):1564-1574. PubMed ID: 28853728
[TBL] [Abstract][Full Text] [Related]
10. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP
Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961
[TBL] [Abstract][Full Text] [Related]
11. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
12. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
[TBL] [Abstract][Full Text] [Related]
13. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment.
Ando Y; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Ishikawa T; Nakano I; Hirooka Y; Goto H
Hepatol Res; 2018 Feb; 48(3):E240-E251. PubMed ID: 28865403
[TBL] [Abstract][Full Text] [Related]
14. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
[TBL] [Abstract][Full Text] [Related]
15. Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment.
Wu JY; Tsai YS; Li CC; Yeh ML; Huang CI; Huang CF; Hsu JN; Hsieh MH; Chen YC; Liu TW; Lin YH; Liang PC; Lin ZY; Chuang WL; Yu ML; Dai CY
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359344
[TBL] [Abstract][Full Text] [Related]
16. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
[TBL] [Abstract][Full Text] [Related]
18. Dynamic evaluation of liver fibrosis to assess hepatocellular carcinoma risk in patients with chronic hepatitis B receiving nucleoside analogs treatment.
Luo J; Yuan M; Li S; Chen L; Zhou M; Li H; Bai X; Zhang Z; Zeng W; Sun X; Zhang Q; Chen Y; Zhou L
Rev Inst Med Trop Sao Paulo; 2024; 66():e27. PubMed ID: 38747848
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract][Full Text] [Related]
20. Gamma-glutamyl transpeptidase-to-platelet ratio and the fibrosis-4 index in predicting hepatitis B virus-related hepatocellular carcinoma development in elderly chronic hepatitis B patients in China: A single-center retrospective study.
Zhu YF; Tan YF; Xu X; Zheng JL; Zhang BH; Tang HR; Yang JY
Medicine (Baltimore); 2019 Dec; 98(50):e18319. PubMed ID: 31852119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
